These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 39318189)

  • 1. CDHu40: a novel marker gene set of neuroendocrine prostate cancer.
    Liu S; Nam HS; Zeng Z; Deng X; Pashaei E; Zang Y; Yang L; Li C; Huang J; Wendt MK; Lu X; Huang R; Wan J
    Brief Bioinform; 2024 Sep; 25(6):. PubMed ID: 39318189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDHu40: a novel marker gene set of neuroendocrine prostate cancer (NEPC).
    Liu S; Nam HS; Zeng Z; Deng X; Pashaei E; Zang Y; Yang L; Li C; Huang J; Wendt MK; Lu X; Huang R; Wan J
    bioRxiv; 2024 Mar; ():. PubMed ID: 38585861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
    Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
    Hsu EC; Rice MA; Bermudez A; Marques FJG; Aslan M; Liu S; Ghoochani A; Zhang CA; Chen YS; Zlitni A; Kumar S; Nolley R; Habte F; Shen M; Koul K; Peehl DM; Zoubeidi A; Gambhir SS; Kunder CA; Pitteri SJ; Brooks JD; Stoyanova T
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2032-2042. PubMed ID: 31932422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
    Zhang W; Liu B; Wu W; Li L; Broom BM; Basourakos SP; Korentzelos D; Luan Y; Wang J; Yang G; Park S; Azad AK; Cao X; Kim J; Corn PG; Logothetis CJ; Aparicio AM; Chinnaiyan AM; Navone N; Troncoso P; Thompson TC
    Clin Cancer Res; 2018 Feb; 24(3):696-707. PubMed ID: 29138344
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival.
    Vlachostergios PJ; Karathanasis A; Tzortzis V
    Genes (Basel); 2022 Jan; 13(1):. PubMed ID: 35052475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the molecular regulators of neuroendocrine prostate cancer.
    Bhattacharya S; Stillahn A; Smith K; Muders M; Datta K; Dutta S
    Adv Cancer Res; 2024; 161():403-429. PubMed ID: 39032955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
    Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
    Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite Prognosis in Prostate Cancers.
    Yang M; Li JC; Tao C; Wu S; Liu B; Shu Q; Li B; Zhu R
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
    Zaidi S; Park J; Chan JM; Roudier MP; Zhao JL; Gopalan A; Wadosky KM; Patel RA; Sayar E; Karthaus WR; Kates DH; Chaudhary O; Xu T; Masilionis I; Mazutis L; Chaligné R; Obradovic A; Linkov I; Barlas A; Jungbluth AA; Rekhtman N; Silber J; Manova-Todorova K; Watson PA; True LD; Morrissey C; Scher HI; Rathkopf DE; Morris MJ; Goodrich DW; Choi J; Nelson PS; Haffner MC; Sawyers CL
    Proc Natl Acad Sci U S A; 2024 Jul; 121(28):e2322203121. PubMed ID: 38968122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Xiao GQ; Ho G; Suen C; Hurth KM
    Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
    Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
    Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
    Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
    Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
    DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
    Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer.
    Asrani K; Torres AF; Woo J; Vidotto T; Tsai HK; Luo J; Corey E; Hanratty B; Coleman I; Yegnasubramanian S; De Marzo AM; Nelson PS; Haffner MC; Lotan TL
    J Pathol; 2021 Dec; 255(4):425-437. PubMed ID: 34431104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.